Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  NASDAQ OMX COPENHAGEN  >  Zealand Pharma A/S    ZEAL   DK0060257814

ZEALAND PHARMA A/S

(ZEAL)
  Report
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq Omx Copenhagen
11/18/2020 11/19/2020 11/20/2020 11/23/2020 11/24/2020 Date
223.4(c) 226(c) 225.8(c) 229.8(c) 224.6 Last
64 906 51 704 46 476 49 599 41 770 Volume
-1.41% +1.16% -0.09% +1.77% -2.26% Change
More quotes
Financials
Sales 2020 386 M 61,6 M 61,6 M
Net income 2020 -613 M -97,9 M -97,9 M
Net cash position 2020 1 244 M 199 M 199 M
P/E ratio 2020 -13,1x
Yield 2020 -
Sales 2021 371 M 59,2 M 59,2 M
Net income 2021 -750 M -120 M -120 M
Net cash position 2021 875 M 140 M 140 M
P/E ratio 2021 -11,7x
Yield 2021 -
Capitalization 9 130 M 1 450 M 1 457 M
EV / Sales 2020 20,4x
EV / Sales 2021 22,3x
Nbr of Employees 329
Free-Float 99,7%
More Financials
Company
Zealand Pharma A/S is a Denmark-based biopharmaceutical company engaged in the discovery, development and commercialization of peptide-based medicines. The Company's pipeline comprises two implementation areas: Cardio-metabolic diseases and Other indications. The Cardio-metabolic diseases area includes medicines for diabetes and obesity treatment, such as Lyxumia (Lixisenatide), Lyxumia/Lantus, ZP2929 and... 
More about the company
Notations Surperformance© of Zealand Pharma A/S
Trading Rating : Investor Rating :
More Ratings
All news about ZEALAND PHARMA A/S
11/20ZEALAND PHARMA A/S : increases its share capital as a consequence of exercise of..
AQ
11/20ZEALAND PHARMA A/S : increases its share capital as a consequence of exercise of..
AQ
11/20Zealand Pharma increases its share capital as a consequence of exercise of em..
GL
11/19Immunicum AB and DCprime Combine Forces to Establish Leader in Cell-Based Can..
AQ
11/12ZEALAND PHARMA A/S : continues to advance clinical programs and commercial launc..
AQ
11/12ZEALAND PHARMA A/S : continues to advance clinical programs and commercial launc..
AQ
11/12Zealand Pharma continues to advance clinical programs and commercial launch c..
GL
11/12ZEALAND PHARMA A/S : to participate in upcoming investor conferences
AQ
11/11ZEALAND PHARMA :
AQ
11/11ZEALAND PHARMA :
GL
11/06ZEALAND PHARMA A/S : hosts conference call on November 12 at 4 pm CET to present..
AQ
11/05ZEALAND PHARMA A/S : hosts conference call on November 12 at 4 pm CET (10am ET) ..
AQ
11/05Zealand Pharma hosts conference call on November 12 at 4 pm CET (10am ET) to ..
GL
11/03Oryzon announces appointment of Dr. Torsten Hoffmann as Global R&D Director a..
AQ
09/18ZEALAND PHARMA A/S : announces amendments to its Articles of Association followi..
AQ
More news
News in other languages on ZEALAND PHARMA A/S
11/16AVIS D'ANALYSTES DU JOUR : Adidas, Alcon, Continental, Engie, Neste, Scout24, St..
10/1410 Biotechs qui font parler d'elles
07/06ZEALAND PHARMA : va ouvrir des bureaux à Boston
06/10ZEALAND PHARMA : signe un accord avec un spécialiste de l'IA
02/10ZEALAND PHARMA : se positionne pour acquérir Valeritas
More news
Chart ZEALAND PHARMA A/S
Duration : Period :
Zealand Pharma A/S Technical Analysis Chart | ZEAL | DK0060257814 | MarketScreener
Technical analysis trends ZEALAND PHARMA A/S
Short TermMid-TermLong Term
TrendsNeutralNeutralNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 7
Average target price 294,14 DKK
Last Close Price 229,80 DKK
Spread / Highest target 55,4%
Spread / Average Target 28,0%
Spread / Lowest Target -2,09%
EPS Revisions
Managers
NameTitle
Emmanuel Dulac President & Chief Executive Officer
Alf Gunnar Martin Nicklasson Chairman
Ivan M. Møller Senior VP-Technical Development & Operations
Matthew D. Dallas Chief Financial Officer & Senior Vice President
Adam Sinding Steensberg Chief Medical & Development Officer, Executive VP
Sector and Competitors
1st jan.Capitalization (M$)
ZEALAND PHARMA A/S-2.38%1 450
GILEAD SCIENCES, INC.-7.83%75 074
VERTEX PHARMACEUTICALS-0.49%56 654
REGENERON PHARMACEUTICALS39.45%55 264
WUXI APPTEC CO., LTD.63.37%39 757
BIONTECH SE214.34%25 644